4D pharma plc (LON: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announced the publication of a paper outlining the mechanism and strong immuno-stimulatory effects of MRx0518.
The paper ‘The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant’ (Lauté-Caly et al) is published in the Nature Publishing Group journal Scientific Reports.
4D researchers demonstrated that MRx0518 stimulates both the innate and adaptive immune systems and identified the bacterial flagellin (a specific component of the MRx0518 bacterium) that interacts with the host TLR5 receptors as a mediator of this process. The TLR5 pathway is known to be associated with the body’s response to cancer.
Dr Alex Stevenson, 4D’s Chief Scientific Officer, commented: “This publication exemplifies our commitment to conducting leading microbiome research and further highlights the importance of a strain-level understanding of function and mechanism in selecting live biotherapeutic candidates for clinical development.”
4D is conducting a number of clinical trials with MRx0518 across a range of settings in 2019. The first of which, a combination study with Keytruda® in collaboration with Merck & Co., Inc., Kenilworth, NJ., USA, and conducted at MD Anderson Cancer Centre, is open for recruitment.
Please find a copy of the paper here: www.nature.com/articles/s41598-018-36926-8
